Manchester United With Big Pharma On Improving Outcomes
The English city's desire to collaborate with the pharmaceutical industry to come up with cost-effective solutions to treat long-term chronic diseases has seen Manchester emerge as a closely watched experiment for the future of health care.
You may also be interested in...
Chris Doherty, managing director of the UK's Alderley Park, tells Scrip that the departure of the drug giant from its global R&D headquarters has acted as a catalyst to create a vibrant biotech cluster that is attractive to local, national and international companies.
Full results from asthma patients included in the Salford Lung Study provide powerful support for the use of “real world” effectiveness studies as a more relevant form of evidence to inform prescribing choices and improve patient outcomes, particularly in what turned out to be a general population of asthmatics that were still suffering symptoms under usual care.
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.